Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO Jun 24, 2021
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer Jun 3, 2021
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer Jun 1, 2021
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic May 26, 2021
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates May 13, 2021
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study Mar 30, 2021
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates Mar 25, 2021
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery Mar 2, 2021
